Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

Central nervous system (CNS) metastases occur frequently in oncogene-driven non-small cell lung cancer (NSCLC). Standard treatment approaches can potentially delay systemic treatment (surgical intervention) or result in neurocognitive impairment (radiotherapy). Recently, next-generation tyrosine kin...

Full description

Bibliographic Details
Main Authors: Omer Gal, Elizabeth Dudnik, Ofer Rotem, Inbar Finkel, Idit Peretz, Alona Zer, Jacob Mandel, Alexandra Amiel, Tali Siegal, Jair Bar, Anastasiya Lobachov, Shlomit Yust
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2020/1980891

Internet

http://dx.doi.org/10.1155/2020/1980891

Similar Items